Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines

Antibacterial medicines should be foundational for modern medicine-a key part of the infrastructure of contemporary practice. Recently, however, antibacterials have struggled commercially. Even with push incentives (grants paid before regulatory approval), antibacterials have failed on the market because revenues are tied to volume sold. There are policy initiatives under way in the United States and United Kingdom that explore paying for exceptional antibacterials with pull incentives (paid after regulatory approval) by delinking the payments from volume via other payment formats such as market entry rewards and subscriptions. This article discusses these initiatives but also proposes an expected net present value model for calculating the global incentives required to create a functional antibacterial market, exploring options such as antibacterial subscriptions, market entry rewards, push incentives, higher prices, and drug development through charitable efforts. The model estimates that current push incentives should be continued, but governments must also enact pull incentives that will add several billion dollars to the global revenue stream of a highly innovative antibacterial, reduced by any grants received supporting clinical development of that product. The amounts in the proposed Pioneering Antibiotic Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 and a UK pilot program are well within the bounds of an effective antibacterial pull incentive.

Automated summary

This article discusses the commercial challenges faced by antibacterials, proposes policy initiatives for pull incentives, and estimates the global incentives required to create a functional market. The model indicates that strengthening pull incentives will have a positive impact on the global revenue stream for innovative antibacterials.